Neuroimaging

You are here

Neuroimaging

 

Recent Headlines

Study: Single season of high school football can damage athlete's brain

The repeated impacts experienced in one season of playing high school football can do significant damage to an athlete’s brain, according to a recent study published by the Journal of Neurotrauma.

Brain injuries may remain unhealed long enough to increase Alzheimer’s risk

Preliminary research at Imperial College London has shown that increased levels in binding of the Alzheimer’s-associated radioligand 11C-PiB—the go-to radioactive biochemical substance in PET imaging for cerebral amyloid beta plaque—also show up in people who have had traumatic brain injury, and for more than a decade after the TBI event. 

Quantitative FET-PET makes the grade for advanced glioma

High-grade astrocytoma is a particularly aggressive form of glioma. Parameters of PET imaging such as the minimal time-to-peak could help clinicians narrow in on the best line of treatment for each patient, according to a study published Dec. 23 in the Journal of Nuclear Medicine.

SPECT goes 3D for improved diagnosis of ADHD

Reading a 3D thresholded SPECT vs. a conventional 2D SPECT has led to a dramatic improvement in sensitivity for the evaluation of attention deficit hyperactive disorder (ADHD), officials at Amen Clinics announced Dec. 9.

Drugs for erectile dysfunction, diabetes could treat vascular dementia

A drug in the same realm as Viagra could treat and perhaps even prevent certain kinds of dementia. Powerful drugs used as a vascular therapy for diabetic patients also may be put to the task, officials from the Alzheimer’s Drug Discovery Foundation (ADDF) and the Alzheimer’s Society UK announced yesterday.

SPECT Alzheimer’s imaging gains more momentum

PET has dominated the amyloid imaging ring for several years now, but a preclinical study is showing some signs that SPECT could give PET a run for its money eventually, especially in translational research, according to a study published Dec. 4 in the Journal of Nuclear Medicine.

Novel PET agent reveals inflammation in Alzheimer’s brain

A new method of Alzheimer’s imaging has arrived with an investigative agent that reveals neuro-inflammation via microglia expression of the protein TSPO, according to a scientific presentation Nov. 17 during Neuroscience 2014, the meeting of the Society of Neuroscience, in Chicago.

Alzheimer’s: Untangling the Research

First came the discovery of beta-amyloid plaque as a precursor of cognitive decline, and then came the tangles of tau and wonderment in researchers’ minds as to their relationship.

First-in-human trial of new serotonin receptor agent

F-18 mefway is a novel serotonin-1A receptor ligand that could one day be used to image neurodegenerative disease and psychiatric disorders, according to a story published Nov. 13 in the Journal of Nuclear Medicine.

NeuroPhage names Franz Hefti new president

The Cambridge, Mass.-based pharmaceutical development company NeuroPhage, which specializes in novel drugs for neurodegenerative disease announced last week that Franz Hefti, PhD, would take the lead as president and chief operating officer.

Pages